SWOG S1826 — Nivolumab-AVD versus brentuximab vedotin-AVD in advanced-stage classic Hodgkin lymphoma

Phase 3 · Hodgkin Lymphoma

Population

Newly diagnosed stage III–IV classic Hodgkin lymphoma.

Primary Endpoint

Progression-free survival

Rationale

Brentuximab vedotin-AVD improved outcomes in advanced Hodgkin lymphoma but carries meaningful toxicity. S1826 compares nivolumab-AVD head-to-head across adolescents and adults to determine the better-tolerated, more effective backbone.

What It Could Change

Established nivolumab-AVD as a new standard of care; ongoing follow-up assesses durability and late effects.